Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease

- Saraf SL, et al. Paediatr Respir Rev. 2014;15(1):4-12.
- Novartis AG. Sickle Cell Disease Around the World. Basel, Switzerland: 2019:1-6
- Piel FB, et al. Lancet. 2013;381(9861);142-151
- Stuart MJ, et al. Lancet. 2004;364(9442):1343-1360.
- National Institutes of Health (NIH). Sickle cell disease. Bethesda, MD. U.S. National Library of Medicine. 2018:1-7.
- Conran N, Franco-Penteado CF, Costa FF. Hemoglobin. 2009;33(1):1-16.
- Ballas SK, et al. Blood. 2012;120(18):3647-3656.
- Elmariah H, et al. Am J Hematol. 2014(5):530-535.
- Steinberg M. New England Journal of Medicine. 1999;340(13):1021-1030.
# # #
Novartis Media Relations E-mail:?media.relations@novartis.comAntonio Ligi Novartis External Communications +41 61 324 1374 (direct) antonio.ligi@novartis.com Jamie Bennett Novartis US External Communications +1 862 778 3503 jamie.bennett@novartis.com | Kara Cournoyer Novartis Institutes for Biomedical Research +1 617 871 3208 (direct) kara.cournoyer@novartis.com Katerina Kontzalis Global Health & CR Communications +41 61 324 1631 (direct) katerina.kontzalis@novartis.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 778 5052 |
Thomas Hungerbuehler | +41 61 324 8425 | ||
Isabella Zinck | +41 61 324 7188 |